Corporate Presentation
Obesity
Survodutide
Survodutide has been evaluated in a Phase 2 trial
in MASH
ZEAL&
ZEALAND PHARMA
Boehringer
Ingelheim
Men and women
18-80 years with
MASH and fibrosis
(NAS ≥4 and
F1-F3) and
BMI ≥25 kg/m²
Survodutide 6.0 mg QW
Survodutide 4.8 mg QW
N=295 R
•
Survodutide 2.4 mg QW
•
Placebo QW
Primary endpoint:
Histological improvement of MASH
without worsening of fibrosis
after 48 weeks of treatment
Secondary endpoints:
.
.
LFC reduction of ≥30% from baseline
Absolute and relative change of LFC
from baseline
≥1 stage decrease in fibrosis stage
(liver biopsy)
Absolute change in NAS
(liver biopsy)
loloo
Screening
(imaging and biopsy)
Dosing
Week 48
(imaging and biopsy)
End of
study
Survodutide is licensed to Boehringer Ingelheim from Zealand Pharma, with Boehringer solely responsible for development and commercialization globally (subject to Zealand's co-promotion rights in the Nordic countries).
Source: ClinicalTrials.gov (NCT04771273), accessed February 2024.
BMI-body mass index; LFC=liver fat content; NAS=NAFLD activity score; MASH=metabolic dysfunction-associated steatohepatitis (formerly NASH, or non-alcoholic steatohepatitis); QW-once-weekly.
31View entire presentation